Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfacytine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfacytine SCHEMBL28251252 | 0.95 | CA1 (0.48) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| Sulfacytine SCHEMBL28122249 | 0.92 | LMNA (0.60) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10697070 | 0.86 | KDM4E (0.51) | MAPTALDH1A1KDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL9806949 | 0.77 | MAPT (0.43) | MAPTSMN1; SMN2 | |
| Sulfachrysoidine SCHEMBL5886196 | 0.77 | MAPT (0.38) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL14639242 | 0.70 | MAPT (0.47) | MAPTALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL11882075 | 0.69 | L3MBTL1 (0.77) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL11884662 | 0.69 | HTR6 (0.52) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10031608 | 0.69 | ALDH1A1 (0.74) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1892698 | 0.68 | FGFR1 (0.44) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4022 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| EP-3841119-A1 | COMPOSITIONS AND METHODS FOR REDUCING BACTERIAL AGGREGATION | La Trobe University (AU) | 2021-06-30 | — | — | EP | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| WO-2020037376-A1 | COMPOSITIONS AND METHODS FOR REDUCING BACTERIAL AGGREGATION | LA TROBE UNIVERSITY (AU) | 2020-02-27 | — | — | WO | claimed |
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-103857440-B | Antimycotic and antibacterium prodrug based on conjugate | 维奥姆生物科学有限公司 | 2018-09-25 | — | — | CN | claimed |
| CN-101094658-B | For improving the medicinal preparation for oral administration of the many microencapsulated form discharging at least one active component | 弗拉梅爱尔兰有限公司 | 2016-10-05 | — | — | CN | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0255100-A2 | Use of trimetrexate and its salts for the preparation of pharmaceutical compositions for treating infections of the mycobacterium-avium-intracellulare complex | WARNER-LAMBERT COMPANY (US) | 1988-02-03 | — | — | EP | claimed |
| US-4039667-A | N-SULFANILYL-1-ETHYL-CYTOSINE | HOFFMANN-LA ROCHE INC. (US) | 1977-08-02 | — | — | US | claimed |